IC Regimen: Delaying Resistance to Lorlatinib in ALK Driven Cancers by Adding Repurposed Itraconazole and Cilostazol.

Kast, Richard E

Kast, Richard E.

Affiliation

Kast RE; IIAIGC Study Center, Burlington, VT 05408, USA.

Cells ; 13(14)2024 Jul 10.

Article in En | MEDLINE | ID: mdl-39056757

Subject(s)

Aminopyridines; Cilostazol; Drug Resistance, Neoplasm; Itraconazole; Humans; Itraconazole/pharmacology; Itraconazole/therapeutic use; Cilostazol/pharmacology; Cilostazol/therapeutic use; Drug Resistance, Neoplasm/drug effects; Aminopyridines/pharmacology; Aminopyridines/therapeutic use; Pyrazoles/pharmacology; Pyrazoles/therapeutic use; Lung Neoplasms/drug therapy; Lung Neoplasms/pathology; Carcinoma, Non-Small-Cell Lung/drug therapy; Carcinoma, Non-Small-Cell Lung/pathology; Drug Repositioning; Lactams/pharmacology; Lactams/therapeutic use; Anaplastic Lymphoma Kinase/metabolism; Anaplastic Lymphoma Kinase/antagonists & inhibitors; Anaplastic Lymphoma Kinase/genetics; Protein Kinase Inhibitors/therapeutic use; Protein Kinase Inhibitors/pharmacology

Key words

ALK kinase; Hedgehog; cilostazol; itraconazole; large cell neuroendocrine cancer; non-small cell lung cancer; platelets

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Itraconazole / Drug Resistance, Neoplasm / Cilostazol / Aminopyridines Limits: Humans Language: En Journal: Cells Year: 2024 Document type: Article Affiliation country: United States Country of publication: Switzerland

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google